Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Safety and preliminary efficacy of a novel loop-optimized, BCMA/CD19 bispecific CAR-T therapy for refractory or relapsed autoimmune diseases patients

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJing PanAZAng ZhangSLSha Li

Discussion

Loading...

Member takes

Overview

Pilot study demonstrates promising safety and efficacy of bispecific CAR-T therapy in systemic lupus erythematosus and systemic sclerosis patients, indicating potential for use in refractory disease.

Key Points

  • Eighty-three percent of systemic lupus erythematosus patients achieved overall response at 1 month post-treatment.
  • Pilot study focused on refractory patients with systemic lupus erythematosus and systemic sclerosis, evaluating safety and efficacy.
  • Assessment of safety involved monitoring for cytokine release syndrome and neurotoxicity, with no severe adverse events found.
  • Promising outcomes include significant B-cell depletion and clinical improvement, urging further investigation.

Cite This Study

Pan et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236ddb2https://doi.org/10.1182/blood-2025-2370
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus2025 · 1 citations
  2. 2BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial2025 · 1 citations
  3. 3Point of care anti-CD19 CAR-T for autoimmune diseases2025
  4. 4CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial2025 · 2 citations
  5. 5Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)2025